Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine

Technologies for enhanced efficacy of DNA vaccines

(2012) Fadi Saade et al.   Expert Review of Vaccines

Novel Antiviral Therapeutics to Control Foot-and-Mouth Disease

(2012) Camila C. Dias et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model

(2012) Chiung-Yi Huang et al.   PLoS One

Human Papillomavirus Immunogen That Provides Protective Tumor Immunity and Induces Tumor Regression

(2012) Juan P. Marquez et al.   VIRAL IMMUNOLOGY

Anticancer function of polyinosinic-polycytidylic acid

(2011) Yu-sheng Cheng et al.   CANCER BIOLOGY & THERAPY

TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer

(2011) B. Salaun et al.   CANCER RESEARCH

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

(2011) M D Fidock et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity

(2011) C. Trumpfheller et al.   JOURNAL OF INTERNAL MEDICINE

Immunotherapy for Cervical Cancer

(2010) Jun-Han Su et al.   BIODRUGS

Toll-Like Receptor Agonists

(2010) Sacha Gnjatic et al.   CANCER JOURNAL

Therapeutic HPV DNA vaccines

(2010) Ken Lin et al.   IMMUNOLOGIC RESEARCH

Protection of Mice by a λ-Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16

(2010) Amir Ghaemi et al.   INTERVIROLOGY

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

(2010) Kavita Tewari et al.   VACCINE

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity

(2009) H. Qin et al.   BLOOD

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC as adjuvant

(2009) M. Paula Longhi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

(2008) Calin D. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toll-like receptors expressed in tumor cells: targets for therapy

(2008) Li Yu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE

The human papillomavirus E7 oncoprotein

(2008) Margaret E. McLaughlin-Drubin et al.   VIROLOGY